Huntington's disease - Symptoms, Causes, Treatment & Prevention

```html

Overview

Huntington’s disease (HD) is a rare, progressive neurodegenerative disorder caused by a mutation in the HTT gene that leads to an abnormal expansion of CAG repeats. The disease primarily affects the brain’s basal ganglia and cerebral cortex, resulting in a triad of motor, cognitive, and psychiatric disturbances.

• Typical age of onset: 30–50 years, but juvenile (<35) and late‑onset (>60) forms exist.
• Inheritance: Autosomal‑dominant – each child of an affected parent has a 50 % chance of inheriting the mutation.
• Prevalence: About 5–10 per 100,000 people of European ancestry; lower in Asian and African populations (<1 per 100,000). The World Health Organization estimates roughly 6–10 million carriers worldwide【1†source】.

Symptoms

Symptoms develop insidiously and worsen over 10–20 years. They are grouped into three major categories:

Motor Symptoms

• Chorea: Involuntary, jerky movements of the face, limbs, and trunk.
• Dystonia: Sustained muscle contractions causing abnormal postures.
• Bradykinesia: Slowness of movement, similar to Parkinson’s disease.
• Impaired gait and balance: Frequent falls, difficulty turning.
• Speech and swallowing difficulties (dysarthria, dysphagia): May lead to weight loss and aspiration.

Cognitive Symptoms

• Executive dysfunction: Trouble planning, multitasking, and problem‑solving.
• Memory deficits: Particularly for recent events.
• Reduced insight: Patients may be unaware of their own deficits.
• Difficulty with attention and concentration.

Psychiatric Symptoms

• Depression: The most common psychiatric manifestation (up to 60 % of patients).
• Anxiety, irritability, and aggression.
• Obsessive‑compulsive behaviors.
• Psychosis: Hallucinations or delusional thinking in later stages.
• Suicidal thoughts: Occur in 10–15 % of patients; requires urgent attention.

Other Manifestations

• Weight loss: Even with normal caloric intake, due to hypermetabolism and swallowing problems.
• Sleep disturbances: Insomnia, REM‑sleep behavior disorder.
• Autonomic dysfunction: Constipation, urinary urgency.

Causes and Risk Factors

Genetic Cause

HD is caused by an expanded CAG trinucleotide repeat in exon 1 of the HTT gene on chromosome 4. Normal alleles contain ≤ 26 repeats; 27–35 repeats are considered intermediate (usually non‑symptomatic but may expand in subsequent generations); ≥ 36 repeats are pathogenic. The larger the repeat size, the earlier the onset and more rapid disease progression.

Who Is at Risk?

• Family history: A first‑degree relative with HD confers a 50 % inheritance risk.
• Repeat length: Individuals with 36‑39 repeats often have a later onset (mid‑50s), whereas > 60 repeats commonly lead to juvenile HD.
• Ethnicity: Highest prevalence in people of Northern European descent.
• Sex: Both males and females are equally affected.

Diagnosis

Because early symptoms can mimic other movement or psychiatric disorders, a systematic approach is essential.

Clinical Evaluation

• Detailed personal and family medical history.
• Neurological examination focusing on chorea, coordination, gait, and speech.
• Psychiatric and neuropsychological testing to document cognitive and mood changes.

Genetic Testing

The definitive test is a molecular DNA analysis for CAG repeat length in the HTT gene. Testing can be performed on:

• Peripheral blood leukocytes.
• Prenatal samples (chorionic villus or amniocentesis) if desired.

Pre‑ and post‑test genetic counseling is strongly recommended, as results have significant emotional and reproductive implications.

Neuroimaging

• MRI: Shows caudate nucleus atrophy and ventricular enlargement; useful for ruling out other conditions.
• CT: Less sensitive but may be used when MRI is contraindicated.

Other Laboratory Tests

There are no blood biomarkers that diagnose HD, but routine labs (CBC, metabolic panel) are performed to exclude metabolic or infectious causes of movement disorders.

Treatment Options

There is currently no cure that halts disease progression, but multidisciplinary care can relieve symptoms, improve quality of life, and prolong functional independence.

Pharmacologic Therapies

• Movement control:
  • Tetrabenazine (approved by FDA) – depletes dopamine to reduce chorea; start low, titrate to effect.
  • Deutetrabenazine – similar efficacy with reduced dosing frequency.
  • Low‑dose antipsychotics (e.g., haloperidol, risperidone) for severe chorea or psychosis.
• Depression & Anxiety: SSRIs (e.g., sertraline, fluoxetine) or SNRIs; psychotherapy is adjunctive.
• Psychosis: Atypical antipsychotics (e.g., quetiapine, olanzapine)—monitor metabolic side effects.
• Sleep disorders: Melatonin or low‑dose trazodone.

All medications should be prescribed by a neurologist or movement‑disorder specialist familiar with HD.

Non‑Pharmacologic Interventions

• Physical therapy: Stretching, balance training, and gait assistance to reduce fall risk.
• Occupational therapy: Adaptive equipment (weighted utensils, dressing aids) to maintain independence.
• Speech‑language therapy: Strategies for dysarthria and safe swallowing.
• Cognitive rehabilitation: Memory aids, structured routines, and computerized brain‑training programs.

Procedural and Surgical Options

• Deep Brain Stimulation (DBS): Experimental for severe, medication‑refractory chorea; evidence remains limited.
• Enteral feeding (PEG tube): Consider when dysphagia leads to aspiration or severe malnutrition.

Lifestyle Modifications

• Balanced, high‑calorie diet with adequate protein to counteract weight loss.
• Regular aerobic exercise (e.g., walking, stationary cycling) to preserve motor function and mood.
• Avoid alcohol and sedating drugs that exacerbate gait instability.
• Maintain a structured daily schedule to reduce confusion and anxiety.

Living with Huntington’s Disease

Practical Daily‑Management Tips

1. Medication organization: Use a weekly pillbox and set alarms.
2. Home safety: Install grab bars, remove loose rugs, improve lighting, and consider a stairlift if needed.
3. Nutrition: Small, frequent, calorie‑dense meals; liquid supplements if swallowing is compromised.
4. Communication: Speak slowly, maintain eye contact, and use simple sentences; consider picture boards for later stages.
5. Support network: Join HD support groups (e.g., Huntington’s Disease Society of America) and involve social workers for care planning.
6. Advance care planning: Discuss legal directives, power of attorney, and end‑of‑life wishes early while capacity is intact.
7. Caregiver self‑care: Respite services, counseling, and caregiver support groups reduce burnout.

Psychosocial Considerations

Depression and suicidal ideation are common; families should maintain open communication, provide reassurance, and seek mental‑health professionals promptly. Educational accommodations (e.g., extended test time, note‑taking assistance) are often required for students with HD.

Prevention

Because HD is genetic, primary prevention is not possible once the mutation is present. However, certain strategies can reduce the *impact* of the disease:

• Pre‑implantation genetic diagnosis (PGD): Couples with a known mutation can use in‑vitro fertilization to select embryos without the pathogenic repeat.
• Genetic counseling: Informs at‑risk individuals about reproductive options and the psychological implications of testing.
• Healthy lifestyle: Regular exercise and balanced nutrition may modestly delay functional decline, though data are limited.

Complications

If left untreated or poorly managed, HD can lead to serious health problems:

• Falls and fractures: Due to chorea, balance loss, and osteoporosis.
• Aspiration pneumonia: From dysphagia and impaired cough reflex.
• Severe weight loss and malnutrition.
• Cardiovascular disease: Increased risk from reduced mobility and metabolic changes.
• Urinary tract infections: Resulting from incomplete bladder emptying.
• Severe psychiatric crises: Depression leading to suicide, or psychosis requiring hospitalization.

When to Seek Emergency Care

References

1. Mayo Clinic. Huntington’s disease. https://www.mayoclinic.org/diseases-conditions/huntingtons-disease
2. National Institute of Neurological Disorders and Stroke (NINDS). Huntington’s Disease Information Page. https://www.ninds.nih.gov/Disorders/All-Disorders/Huntingtons-Disease-Information-Page
3. World Health Organization. Genetic Disorders: Huntington’s disease. 2022.
4. Cleveland Clinic. Treatment options for chorea in Huntington’s disease. https://my.clevelandclinic.org/health/diseases/16447-huntingtons-disease
5. Huntington’s Disease Society of America. Guidelines for Care and Lifestyle. 2021.
6. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Huntington’s Disease. 2020.

```